This site is for Canadian Healthcare Professionals.

Your patients may still be at risk. Let’s help keep them protected against COVID‑19.

Spikevax DASH Document
Share this site

Spikevax (COVID-19 mRNA vaccine) is indicated for active immunization against coronavirus disease 2019 (COVID-19) caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) virus in individuals 6 months of age and older.1

Let’s stay tough, Canada

At Moderna, we’re proud of our new consumer awareness campaign encouraging Canadians to ask about COVID-19 vaccination. We’re even more proud to partner with you to help support the health of your patients.

COVID-19 is still active in Canada

Despite feeling like a thing of the past, COVID-19 is still circulating.2 Some individuals may only experience asymptomatic to mild disease, while others continue to be at increased risk for severe illness.3 In fact, COVID-19 continues to drive a high number of hospitalizations compared to other respiratory viruses – with adults aged ≥65 years shouldering the highest level of burden.3,4

View the latest COVID-19 Surveillance Report

Identifying patients at increased risk for severe COVID-19 infection3,5,6*

While anyone can be infected, some populations are at increased risk for SARS-CoV-2 exposure and/or severe COVID-19 disease and outcomes. For some patients, risks factors may overlap – further increasing their overall risk.3,5,6

Increased risk of exposure3,5
Increased risk of severe disease3,5,6
Situational Factors
e.g., congregate living (long-term care homes or other congregate living settings); occupational settings (healthcare workers or other care providers in facilities or community settings)†
Biological factors
e.g., aged ≥65 years; underlying medical conditions†

Social factors

e.g., socioeconomic status; belonging to a racialized population (First Nations, Inuit and Métis communities or other equity-denied communities)†

Underlying medical conditions associated with severe COVID-19 disease according to PHAC6

Think C•O•V•I•D to help recall at-risk medical conditions6

C

CANCER & CHRONIC DISEASE

  • Cancer
  • Chronic disease (kidney disease; liver diseases [cirrhosis, non-alcoholic fatty liver disease, alcoholic liver disease, and autoimmune hepatitis]; lung diseases [bronchiectasis, COPD, ILD, pulmonary hypertension, PE]; cystic fibrosis; diabetes mellitus, [types 1 and 2]; heart conditions [e.g., cardiomyopathies, HF]; smoking [current or former])

O

OBESITY & OBSTETRICS

  • Obesity (BMI ≥30 kg/m2)
  • Pregnancy and recent pregnancy

V

VASCULAR DISEASE & VULNERABILITIES

  • Vascular disease (coronary artery disease; cerebrovascular disease)
  • Medical and/or social vulnerabilities (e.g., people who use substances regularly; persons experiencing homelessness or who are unhoused)

I

INFECTION & IMMUNO-COMPROMISED

  • Infection (HIV; tuberculosis)
  • Immunocompromised (primary immunodeficiency diseases; solid organ or blood stem cell transplant); immunosuppressive medications (e.g., corticosteroids)

D

DISABILITIES & DISORDERS

  • Disabilities (e.g., Down syndrome, learning, intellectual, or developmental disabilities; ADHD; cerebral palsy; congenital disabilities; spinal cord injuries)
  • Mental health disorders (mood disorders, e.g., depression; schizophrenia spectrum disorders)

Adapted from the Public Health Agency of Canada (PHAC).6

COPD=chronic obstructive pulmonary disease; ILD=interstitial lung disease; PE=pulmonary embolism; HF=heart failure; BMI=body mass index; ADHD=attention-deficit/hyperactivity disorder; NACI=National Advisory Committee on Immunization; PHAC=Public Health Agency of Canada.
* The effectiveness and safety of Spikevax in at-risk populations has not been evaluated in clinical trials.
† Those individuals aged ≥6 months.

Still recommended for eligible patients.5

Now available in two convenient formats.1

The Spikevax (COVID-19 mRNA vaccine) formulation remains available for patients who are eligible for vaccination – and is available in a Canadian-made pre-filled syringe.

NACI guidance on the use of COVID-19 vaccines starting fall 20265*

Recommendations for public health program decision-making

STRONG recommendations

WHO SHOULD RECEIVE ≥1 DOSE OF COVID-19 VACCINE

Individuals at increased risk of SARS-CoV-2 exposure or severe COVID-19 disease, including:

All adults aged ≥65 years

Those aged ≥6 months who:

reside in congregate living settings or long-term care homes
are pregnant
are healthcare workers or care providers in facilities and community settings
are with underlying medical conditions, including children with complex needs†
are in or from First Nations, Inuit, and Métis communities†
are members of racialized or equity-denied communities

WHO SHOULD RECEIVE A 2ND DOSE OF COVID-19 VACCINE PER YEAR

All adults aged ≥80 years

Adult residents of long-term care homes and other in congregate living settings for seniors
Individuals aged ≥6 months who are moderately to severely immunocompromised (due to an underlying medical condition)
NEW: Adults aged 65–79 years with underlying medical condition that place them at higher risk for severe COVID-19

DISCRETIONARY recommendations

WHO MAY RECEIVE COVID-19 VACCINE

Individuals aged ≥6 months who are not included in the populations listed above

Adults aged 65 to 79 years

Recommendations to support individual decision-making

DISCRETIONARY recommendation

Individuals aged ≥6 months (not included in the populations listed above) may also receive the COVID-19 vaccine.

  • Choice to receive the vaccine may be based on individual COVID-19 risk assessment or preference

Vaccination timing & considerations

  • The minimum interval between COVID-19 doses is 3 months; evidence suggests vaccine protection wanes after approx. 4–6 months
  • When deciding on the best time to get vaccinated, individuals may consider factors such as
    • time since their last dose; individuals who have not previously been vaccinated may be offered a COVID-19 vaccine dose at any time
    • anticipated exposure (e.g., travel) or immunocompromised status (e.g., planned immunosuppressive therapy)

For the full statement, consult the Guidance on the use of COVID-19 vaccines starting fall 2026.

Quebec Immunization Committee (CIQ)

CIQ recommendations on COVID-19 vaccination for the 2026–27 season

Access now

* Provincial/territory criteria may vary. Refer to your regional health authority for complete eligibility criteria.
† There is limited evidence on clinical risk factors for severe COVID-19 disease in pediatric populations. Children at increased risk for severe outcomes may include children who are medically fragile/have medical complexities, children with more than one comorbidity, children with neurological disorders, children with chronic lung disease, and children with Down syndrome (Trisomy 21), and other immunocompromising conditions.
‡ Autonomous decisions should be made by Indigenous Peoples with the support of healthcare and public health partners in accordance with the United Nations Declaration on the Rights of Indigenous Peoples Act.

COVID-19 vaccine programs by province/territory: summary of 2026/27 eligibility criteria

To view the eligibility criteria for your area, please select from the list of provinces and territories.
 
Important: eligibility criteria may changeat undefined times. Always consult with your regional health authority for the latest information.

Select an area

Eligibility Summary

Select a province to see eligibility criteria

We're here to help!

Please contact us if you have any questions about ordering and product availability or to arrange an appointment with our field staff.

Email

WeCare@modernatx.com

Phone

1-866-MODERNA (1-866-663-3762)8:00 AM - 8:00 PM ETMonday - Friday (closed holidays)

Prescribing Information

Indication and clinical use:

Spikevax® (COVID-19 mRNA vaccine) is indicated for active immunization against coronavirus disease 2019 (COVID-19) caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) virus in individuals 6 months of age and older.

Pediatrics: Safety and efficacy in individuals <6 months of age have not yet been established.

Contraindication:

  • Hypersensitivity to the active ingredient or to any ingredients in the formulation, including any non-medicinal ingredient, or component of the container.

Relevant warnings and precautions:

  • Hypersensitivity and anaphylaxis
  • Myocarditis and pericarditis
  • Patients with acute infection
  • Patients with hematologic disorders or on anticoagulant therapy
  • Patients who are immunocompromised
  • Syncope
  • Vaccination with Spikevax may not protect all recipients

For more information:

Consult the Product Monograph at spikevaxpro.com/pm for important information regarding adverse reactions, drug interactions, and dosing, which have not been discussed in this piece. The Product Monograph is also available by calling us at 
1-866-MODERNA (1-866-663-3762).

References

  1. Spikevax Product Monograph. Moderna Biopharma Canada Corp.
  2. Government of Canada. Canadian respiratory virus surveillance report: COVID-19. Available at: https://health-infobase.canada.ca/respiratory-virus-surveillance/covid-19.html. Accessed July 14, 2026.
  3. Public Health Agency of Canada (PHAC). COVID-19 vaccines: Canadian Immunization Guide. Available at: https://www.canada.ca/en/public-health/services/publications/healthy-living/canadian-immunization-guide-part-4-active-vaccines/page-26-covid-19-vaccine.html. Accessed July 14, 2026.
  4. Public Health Agency of Canada: The Canadian Nosocomial Infection Surveillance Program (CNISP). Weekly CNISP viral respiratory infection (VRI) data. Available at: https://health-infobase.canada.ca/cnisp/viral-respiratory-infections.html. Accessed September 10, 2025.
  5. National Advisory Committee on Immunization (NACI), An Advisory Committee Statement (ACS): Guidance on the use of COVID-19 vaccines starting fall 2026. Published June 2026.
  6. Public Health Agency of Canada (PHAC). COVID-19 signs, symptoms and severity of disease: A clinician guide. Available at: https://www.canada.ca/en/public-health/services/diseases/2019-novel-coronavirus-infection/guidance-documents/signs-symptoms-severity.html#a3. Accessed July 13, 2026.
  7. Alberta Health Services. Respiratory virus season – Get vaccinated. Available at https://www.alberta.ca/respiratory-virus-season-get-vaccinated#jumplinks-3. Accessed September 14, 2026.
  8. Government of British Columbia. COVID-19 immunizations. Available at: https://www2.gov.bc.ca/gov/content/health/managing-your-health/immunizations/covid-19-immunization. Accessed October 5, 2026.
  9. Province of Manitoba. COVID-19 vaccine eligibility, vaccine schedule, and proof of vaccination. Available at: https://www.gov.mb.ca/covid19/vaccine.html. Accessed October 5, 2026.
  10. Government of New Brunswick. COVID-19 Vaccine. Available at: https://www.gnb.ca/en/topic/health-wellness/immunization-vaccination/covid-19-vaccine.html. Accessed September 14, 2026.
  11. Government of Newfoundland and Labrador. Time for the shot: COVID-19. Available at: https://www.timefortheshot.ca/covid-19/. Accessed October 5, 2026.
  12. Nova Scotia Health. COVID-19 vaccines. Available at: https://www.nshealth.ca/coronavirusvaccine. Accessed October 15, 2026.
  13. Health and Social Services. NWT Immunization Schedule. Available at: https://www.hss.gov.nt.ca/en/services/immunization-vaccination/nwt-immunization-schedule. Accessed September 16, 2026.
  14. Government of Nunavut. Drug Formulary – Vaccines and Immune Globulins. Available at: https://www.gov.nu.ca/en/listing-formulary-vaccines-and-immune-globulins. Accessed October 5, 2026.
  15. Ontario Ministry of Health. COVID-19 vaccines. Available at: https://www.ontario.ca/page/covid-19-vaccines#section-1. Accessed September 14, 2026.
  16. Government of Prince Edward Island. Flu, COVID-19, and RSV vaccination. Available at: https://www.princeedwardisland.ca/en/information/health-pei/flu-covid-19-and-rsv-vaccination#utm_source=redirect&utm_medium=url&utm_campaign=flu. Accessed October 5, 2026.
  17. Government of Quebec. COVID-19 vaccination. Available at: https://www.quebec.ca/en/health/advice-and-prevention/vaccination/covid-19-vaccine#c233194. Accessed October 5, 2026.
  18. Government of Saskatchewan. Seasonal Immunization Program. Available at:https://www.saskatchewan.ca/residents/health/accessing-health-care-services/immunization-services/immunization-programs. Accessed October 15, 2026.
  19. Government of Yukon. Book a vaccine appointment. Available at: https://yukonimmunization.ca/appointments. Accessed October 5, 2026.

Stay up to date with Moderna Canada

Sign up if you are interested in being contacted by Moderna to receive scientific, medical and promotional information, including invitations to medical education events or webinars and information on opportunities for scientific, medical and promotional engagements.

By submitting your information, you agree to Moderna’s Terms and Conditions. You also acknowledge that your information will be processed in accordance with Moderna’s Privacy Statement. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.